Abbott: Clinical Trials

121 trials sponsored by Abbott, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

91 completed, 20 terminated, 6 unknown, 3 withdrawn. 121 Phase 2, 21 Phase 3, 10 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2121Completed 91, Terminated 20, Unknown 6, Withdrawn 3, Recruiting 1
Phase 321Completed 16, Unknown 5
Phase 110Completed 6, Terminated 4

Follow Abbott: new trials by email

Trials (filtered) newest first · largest first

All 121 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries.
Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets, Stratification and standard care - Myocardial Infarction, Acute, Myocardial Infarction With Nonobstructive Coronary Arteries
Phase 2RecruitingNHS National Waiting Times Centre Board4002022-02-042026-03-16
The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study
Omega-3 fish oil, Losartan, Corn Oil (Fish oil Placebo) - Inflammation
Phase 2CompletedUniversity of Florida2892016-04-262024-05-07
Bioabsorbable Everolimus-Eluting Stents for Internal Pudendal Artery-Related Arteriogenic Erectile Dysfunction
Bioabsorbable everolimus-eluting stent deployment - Impotence, Arteriogenic
Phase 2 / Phase 3UnknownNational Taiwan University Hospital152015-07-012015-07-08
Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Creon IR, Creon® (DR/GR) - Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
Phase 2CompletedAbbott702015-03-012016-04-04
Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)
MTX 12.5, MTX 25, Adalimumab - Ulcerative Colitis
Phase 2TerminatedAlimentiv Inc.222013-06-012021-06-23
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
Veliparib, Topotecan - Ovarian Cancer
Phase 1 / Phase 2CompletedVejle Hospital222012-11-012015-06-10
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
everolimus, letrozole plus leuprolide, combination of everolimus, letrozole and leuprolide - Fibrolamellar Carcinoma, Fibrolamellar Liver Cancer
Phase 2CompletedMemorial Sloan Kettering Cancer Center282012-07-122022-12-29
EARNEST Rifabutin Pharmacokinetics (PK) Substudy
Rifabutin - HIV, Tuberculosis
Phase 2UnknownJustine Boles1402011-12-012012-08-13
Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation
Veliparib - Recurrent, Epithelial Ovarian Cancer
Phase 1 / Phase 2CompletedVejle Hospital492011-11-012016-11-16
Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes
Paricalcitol, placebo - Type 2 Diabetes
Phase 2CompletedMario Negri Institute for Pharmacological Research1122011-09-012017-03-03
Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis
Anti-tumor necrosis factor alpha monoclonal antibody, placebo - Uveitis, Juvenile Arthritis
Phase 2 / Phase 3CompletedAssistance Publique - Hôpitaux de Paris342011-06-292025-09-08
ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)
Adalimumab, Methotrexate, Placebo - Oligoarthritis
Phase 2CompletedUniversity of Leeds222011-06-012019-11-07
ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
ABT-888, mFOLFOX-6 - Metastatic Pancreatic Cancer
Phase 1 / Phase 2CompletedGeorgetown University642011-01-032025-11-06
Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut
FITC-Adalimumab - Crohn's Disease
Phase 1 / Phase 2CompletedUniversity of Erlangen-Nürnberg Medical School252011-01-012012-09-14
Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease
Zemplar - Chronic Kidney Disease
Phase 2 / Phase 3CompletedDanderyd Hospital362010-09-012013-09-05
ABT-888 and Temozolomide for Liver Cancer
Temozolomide, ABT-888 - Hepatocellular Carcinoma
Phase 2TerminatedGeorgetown University162010-08-012025-02-12
To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
veliparib, Temozolomide - Solid Tumor Cancers
Phase 2CompletedAbbott242010-07-012012-11-21
Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen
ABT-263 - B-cell Chronic Lymphocytic Leukemia
Phase 2WithdrawnAbbott1502010-03-012010-02-26
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
ABT-888, temozolomide - Breast Cancer, Metastatic Breast Cancer
Phase 2CompletedSteven J Isakoff, MD, PhD632009-11-012025-03-14
Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children
palivizumab - Respiratory Syncytial Virus Infection, Premature Birth
Phase 2 / Phase 3CompletedAbbott1002009-11-012011-07-19

Showing 20 of 121. Sign in to see all of them.

Conditions studied

HIV Infections (15)  ·  Psoriasis (7)  ·  Crohn Disease (5)  ·  Renal Insufficiency, Chronic (5)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Dysmenorrhea (4)  ·  Endometriosis (4)  ·  Pelvic Pain (4)  ·  Prostatic Neoplasms (4)  ·  Alzheimer Disease (3)  ·  Arthritis, Rheumatoid (3)  ·  Attention Deficit Disorder with Hyperactivity (3)  ·  Carcinoma, Renal Cell (3)  ·  Dyspareunia (3)  ·  Hyperparathyroidism, Secondary (3)

Interventions

Adalimumab (22)  ·  paricalcitol (11)  ·  Lopinavir (8)  ·  asoprisnil (8)  ·  ABT751 (7)  ·  Ritonavir (7)  ·  lopinavir-ritonavir drug combination (7)  ·  veliparib (7)  ·  efavirenz (6)  ·  pozanicline (5)  ·  Temozolomide (4)  ·  Valproic Acid (4)  ·  Atrasentan (3)  ·  Hydrocodone (3)  ·  Lamivudine (3)

Countries

United States (64)  ·  Canada (11)  ·  Japan (10)  ·  Germany (7)  ·  France (6)  ·  United Kingdom (6)  ·  Italy (5)  ·  Netherlands (5)  ·  Spain (5)  ·  Denmark (4)  ·  Poland (4)  ·  Puerto Rico (4)  ·  Argentina (3)  ·  Australia (3)  ·  Brazil (2)

Top investigators

Helen Eliopoulos, MD (4)  ·  Mihail Obrocea, MD (3)  ·  Rita Jain, MD (3)  ·  Rod Humerickhouse, MD (3)  ·  Eugene Sun, M.D. (2)  ·  Kathryn J Swoboda, M.D. (2)  ·  Kazuko Kobayashi (2)  ·  Shigeki Hashimoto, Ph.D. (2)  ·  Aiwu R He, MD PhD (1)  ·  Anders Jakobsen, DMSc (1)  ·  Anders Jakobsen, MD, DMSc (1)  ·  Barbara A da Silva, M.D. (1)  ·  Barbara da Silva, M.D. (1)  ·  Beatrice Rendenbach-Mueller, PhD (1)

Results publications

PMID 22325170, PMID 27338778, PMID 29380251, PMID 17307170, PMID 17339234, PMID 18018771, PMID 18434903, PMID 18540803, PMID 18576337, PMID 19512937, PMID 20186346, PMID 20808854, PMID 21055801, PMID 21346607, PMID 21748252, PMID 21754985, PMID 22344964, PMID 22913981, PMID 22943074, PMID 23147218, PMID 23247938, PMID 23504383, PMID 23686466, PMID 23766338, PMID 23787544, PMID 24476416, PMID 24746976, PMID 24751453, PMID 24874893, PMID 25486412, PMID 25838291, PMID 25973909, PMID 26449224, PMID 26496210, PMID 26547918, PMID 26977746, PMID 27136622, PMID 28511692, PMID 29104158, PMID 29275333, PMID 29386411, PMID 29579325, PMID 29767684, PMID 30104007, PMID 30541065, PMID 30608620, PMID 30968368, PMID 31370809, PMID 33270906, PMID 34417675

NIH funding

2008 (3), 2005 (1), 2009 (1), 2014 (1), P30AI050410 (1), R01AI064074 (1), U01AG050499 (1), U01AI067854 (1)